GSK plc ($GSK)

HR8024 authorizes $85M total over 5 years for maternal vaccination awareness campaigns - an amount too small to move revenue for major vaccine manufacturers. The bill has one sponsor (Rep. Sewell, D-AL), was referred to committee on 2026-03-19, and has no appropriations guarantee. No market impact.

→ No revenue-linked mechanism for GSK's maternal vaccines (RSV and Tdap); $17M/year is spread across all maternal vaccine types and educational efforts

The Protecting Americans from Unsafe Drugs Act of 2026 (HR7980) would expand FDA mandatory recall authority from controlled substances to all drugs, increasing structural operational risk and compliance costs for major pharmaceutical manufacturers. The bill is at an early legislative stage with a single Democratic sponsor, giving it low near-term passage probability. Market data shows the sector is already under pressure in April 2026 with JNJ, PFE, MRK, and AZN all down significantly over 30 days, but this bill is not yet being priced in as a material risk.

→ Manufacturers face increased compliance costs for recall infrastructure and higher potential liability from mandatory recalls.

The EPIC Act of 2025 would extend small-molecule drug exclusivity before Medicare price negotiation from 7 to 11 years for drugs approved after 2028. Despite sector-wide 30-day declines ($MRK -7.18%, $GSK -5.02%, $PFE -4.24%), the bill's early-stage status (referred to Senate Finance Committee) and long legislative path mean no near-term revenue impact. The structural beneficiary is clear: small-molecule-focused pharma pipelines gain 4 additional years of un-negotiated pricing.

→ Small-molecule drugs approved after 2028 will have an additional 4 years of market exclusivity before facing mandatory price negotiation with CMS, delaying potential revenue erosion from government-set prices.

HR7385 is an early-stage bill authorizing up to $10M per grant for PrEP programs, with no specified total funding or direct corporate beneficiaries. It has been referred to committee with 14 cosponsors, all Democrats. At this procedural stage, the bill has no measurable market impact.

HR6052, the Elijah E. Cummings Family Asthma Act, is an early-stage bill that amends the Public Health Service Act to direct further asthma research. It authorizes no specific funding, mandates no changes to healthcare providers or pharmaceutical companies, and has been referred to committee with four cosponsors. No near-term market impact is expected.

The End the Vaccine Carveout Act (HR 4668) is an early-stage bill with 29 cosponsors that would eliminate the PREP Act liability shield for vaccine manufacturers, exposing $PFE, $MRNA, $GSK, and $JNJ to direct civil lawsuits for vaccine-related injuries. The bill has no near-term passage probability — it was referred to committee in July 2025 with zero further action — but its reintroduction signals continued legislative risk for the vaccine liability framework. Real market data shows all four tickers are down over the trailing 30 days ($PFE -5.09%, $MRNA -7.03%, $GSK -5.16%, $JNJ -5.87%), consistent with broader pharma weakness rather than a discrete bill-event reaction.

→ Direct litigation exposure across GSK's entire vaccine portfolio (annual sales ~$9.6B in 2024); Shingrix ($3.5B revenue) is a blockbuster with large patient exposure. Removing PREP Act shield exposes the company to punitive damage claims